CROI 2012: Hep C Drug Incivek Improves HCV Cure Rate in People With HIV
March 26, 2012
Results from a small study of 62 co-infected people treated with Incivek showed that 74% had undetectable viral loads at 12 weeks after stopping their hepatitis C treatment, compared to 45% on pegylated interferon + ribavirin alone. About one-quarter were not on HIV treatment (13) while most (47) were taking Atripla or boosted Reyataz (atazanavir) + Truvada (Viread/tenofovir + Emtriva/emtricitabine).
Incivek + pegylated interferon + ribavirin was given for the first 12 weeks, and then interferon + ribavirin only for the next 36 weeks. The average age of the participants was 45, and only 15% were women. Most people had HCV viral loads above 800,000, while 10% had advanced liver fibrosis. Nearly 68% had HCV genotype 1a while the others had 1b, both of which are more difficult to treat types.
The following chart describes 12-week post-treatment undetectable HCV viral loads (T/PR = Incivek + pegylated interferon + ribavirin):
Larger studies will be conducted. These will include people new to HCV treatment, people who rebounded after HCV treatment, partial responders, and non-responders.
This article was provided by Project Inform. Visit Project Inform's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)